Indeed, there are accompanying clinical trials that either use mutant IDH inhibitors alone, target different pathways that are altered in IDH-mutant gliomas, such as DNA damage pathways or epigenetic pathways, or test the effects of combinatorial approaches in IDH-mutant tumors. This evidence concerns the gene IDH2 and central nervous system cancer.